Seagen Highlights First Solid Tumor Data For An ADCETRIS Immunotherapy Combination And Preclinical Data For Novel CD30-Directed Antibody-Drug Conjugate At Society For Immunotherapy Of Cancer Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Seagen Inc. (NASDAQ:SGEN) presented initial Phase 2 data for ADCETRIS in combination with immunotherapy pembrolizumab in metastatic non-small cell lung cancer and metastatic cutaneous melanoma at the Society for Immunotherapy of Cancer Annual Meeting. The company also shared preclinical data for a novel antibody-drug conjugate SGN-35T. The combination of ADCETRIS and a PD-1 inhibitor showed promising results, supporting continued research. Seagen plans to begin enrolling patients in a phase 1 clinical trial for SGN-35T soon.
November 03, 2023 | 4:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Seagen's presentation of promising Phase 2 data for ADCETRIS and preclinical data for SGN-35T could potentially boost investor confidence in the company's research and development capabilities.
The promising results from the Phase 2 trial of ADCETRIS and the preclinical data for SGN-35T indicate that Seagen is making significant progress in its research and development efforts. This could potentially lead to increased investor confidence in the company, which could positively impact the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100